No 'additive' cardioprotective effect of GLP-1RA on background use of SGLT2i in HARMONY, AMPLITUDE-O and most recently SOUL.

Cardioprotective effects of GLP-1RA are 'independent' of SGLT2i

ahajournals.org/doi/epdf/10.11…
10.1016/j.jacc.2023.05.048

Warrior trial PEP result shown below.
Is this a NULL trial or a NEGATIVE trial?
Trial powered for HR 0.80 which was excluded by 95% CI
How many null or negative PRAGMATIC trials before we seriously consider/scrutinize the utility of such trials?

Imagine if I excluded centers in a multicenter trial of SAVR vs TAVR where TAVR outperformed SAVR, I could show that SAVR was superior to TAVR in high-risk patients with AS (PARTNER-1A).